Information Provided By:
Fly News Breaks for April 29, 2019
PVAC, SILK, TW, NGM, IOVA
Apr 29, 2019 | 10:29 EDT
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Iovance Biotherapeutics (IOVA) initiated with an Overweight at Piper Jaffray. 2. Tradeweb Markets (TW) initiated with a Market Perform at Wells Fargo, a Hold at Jefferies and Sandler O'Neill, an Equal Weight at Morgan Stanley and Barclays, as well as a Neutral at BofA/Merrill, Goldman Sachs, Credit Suisse, and Citi. 3. Penn Virginia (PVAC) initiated with an Outperform at Imperial Capital. 4. NGM Biopharmaceuticals (NGM) initiated with an Outperform at Cowen as well as a Buy at Goldman Sachs and Citi. 5. Silk Road Medical (SILK) initiated with an Overweight at JPMorgan, an Outperform at BMO Capital, a Buy at Stifel, and a Neutral at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
News For IOVA;TW;PVAC;NGM;SILK From the Last 2 Days
TW
Jun 17, 2019 | 16:54 EDT
Raymond James analyst Patrick O'Shaughnessy started Tradeweb Markets with a Market Perform rating saying the company is "attractive" but trades at a "premium" valuation.
SILK
Jun 16, 2019 | 13:35 EDT
Silk Road Medical announced final results for the company's ROADSTER-2 post-marketing study evaluating real world use of the ENROUTE Neuroprotection and Stent Systems in TransCarotid Artery Revascularization procedures. The study demonstrated compelling patient outcomes with low stroke and combined stroke and death rates of 0.6% and 0.8%, respectively, in 632 high surgical risk patients enrolled across 42 sites. 70% of patients enrolled in the study were from physicians new to TCAR. Designed as a follow-on study to the pivotal ROADSTER trial, ROADSTER-2 is a prospective, multi-center study designed to assess the real-world usage of the ENROUTE Transcarotid Stent when used with the ENROUTE Transcarotid Neuroprotection System by physicians of varying experience with the TCAR procedure. The study met its primary endpoint of procedural success, defined as acute device and technical success in the absence of stroke, death or myocardial infarction at 30 days, at 97.9%. Significant findings from the study showed TCAR to have low rates of 30-day major adverse events. In addition, ROADSTER-2 showed lower rates of acute and permanent cranial nerve injury than is typically observed for patients receiving carotid endarterectomy, the current standard of care.